Abstract 139P
Background
Combining local thermal ablation with immune checkpoint inhibitors for small hepatocellular carcinoma is uncharted territory. This phase II trial aimed to evaluate the safety and efficacy of combining thermal ablation with tislelizumab, an anti-PD-1 antibody, in patients with Barcelona Clinic Liver Cancer stage A or B HCC.
Methods
This phase II trial (NCT04652440) included newly diagnosed and recurrent HCC patients with 1 or 2 lesions measuring 2-5 cm. Patients received their first tislelizumab dose intravenously within one day before percutaneous thermal ablation, followed by infusions every three weeks for a total of four doses. Primary endpoints were safety and tolerability. Secondary endpoints included complete response rate by first thermal ablation, local recurrence rate, distant metastasis rate, and 1- and 2-year disease-free survival and overall survival rates. This study was presented as a poster at ESMO Asia 2023 in Singapore, and this is an update on the present study.
Results
The study completed recruiting 30 HCC patients in August 2023. The CR1 was 93.33%, with 26 patients (86.67%) completing the entire treatment. One patient discontinued due to a severe adverse event related to thermal ablation and did not receive further medication, while another switched to resection after a second failed ablation. By the data cut-off on May 27, 2024, 23 patients (76.7%) experienced grade ≥3 treatment-related adverse events. The most common were elevated alanine aminotransferase (N=16) and aspartate aminotransferase (N=23) levels on the first-day post-ablation, with most recovering after supportive treatment. Additionally, 12 patients experienced grade 1-2 immune-related adverse events (irAEs), including rash (N=9), pruritus (N=6), and anorexia (N=4), with no grade ≥3 irAEs reported. One patient developed renal failure six months after the last dose of tislelizumab and was diagnosed with multiple myeloma, likely unrelated to the study treatment. The one-year DFS rate was 71.4% (95% confidence interval, 56.4% to 90.4%).
Conclusions
Combining thermal ablation with tislelizumab showed acceptable safety and tolerability, with no unexpected SAEs. Long-term outcomes will be disclosed in the future.
Clinical trial identification
NCT04652440.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract